Bristol-Myers Squibb is aiming to recapture its leadership in oncology by focusing on developing novel cytotoxic agents as well as concentrating on the emerging field of targeted therapies, Chief Scientific Officer Elliott Sigal said during a post-ASCO call
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US, including potentially introducing new intermediaries into the system. Questions on MFN's feasibility and why it may be “catastrophic” to biopharma were also part of the discussion
Quick responses to late-breaking changes to US FDA COVID-19 vaccine policy kept Novavax's Nuvaxovid and Moderna's mNexspike close to expected approval timelines despite revised indications and new post-marketing trial commitments.
The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.
